Reaction

Graft Versus Host Disease In Gastrointestinal Tract reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,101 reports · 106 co-occurring drugs

As of the last recalculation, Graft Versus Host Disease In Gastrointestinal Tract appears in 2,101 FAERS reports alongside 106 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 273.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Thiotepa	234	273.0	279.9
Busulfan	343	257.9	263.7
Fludarabine Phosphate	673	249.0	253.3
Melphalan	194	93.0	93.8
Mycophenolate Mofetil Hydrochloride	776	89.0	89.5
Mycophenolate Mofetil	775	89.0	89.5
Sirolimus	111	86.1	86.8
Melphalan Hydrochloride	195	84.8	85.5
Alemtuzumab	151	83.3	83.9
Posaconazole Delayed-Release	83	77.9	78.5
Cyclosporine	619	77.7	78.2
Tacrolimus Ointment 0.1%	637	72.3	72.7
Tacrolimus Extended-Release Capsules	638	72.3	72.6
Ganciclovir	70	70.1	70.5
Ganciclovir Sodium	71	68.8	69.2
Posaconazole	104	66.7	67.1
Tacrolimus	690	64.5	64.8
Blinatumomab	62	60.6	61.0
Amphotericin B	66	53.8	54.1
Mycophenilic Acid	94	47.0	47.2
Anti-Thymocyte Globulin (Rabbit)	37	46.2	46.4
Basiliximab	53	45.8	46.0
Methylprednisolone	419	37.3	37.4
Micafungin Sodium	30	35.5	35.7
Voriconazole Injection	75	35.4	35.6
Cyclophosphamide Injection, Solution	479	34.4	34.5
Cyclophosphamide	479	34.4	34.5
Cyclophosphamide For Injection	479	34.4	34.5
Ruxolitinib	223	34.4	34.5
Mycophenolic Acid	101	32.8	32.9
Valganciclovir Hydrochloride Powder,	37	30.6	30.7
Voriconazole	89	30.3	30.4
Budesonide	141	25.3	25.4
Cytarabine	138	24.3	24.3
Valganciclovir	45	24.1	24.2
Valganciclovir Hydrochloride	45	24.1	24.2
Anakinra	39	23.7	23.8
Meropenem	68	21.7	21.7
Azacitidine	61	20.9	21.0
Ursosiol	36	18.6	18.7
Canakinumab	20	18.5	18.5
Atovaquone	14	17.3	17.4
Azacitidine For	31	17.1	17.1
Ursodiol	37	17.1	17.1
Polatuzumab Vedotin	16	16.4	16.4
Fluconazole	106	15.7	15.7
Etoposide	106	15.0	15.0
Methotrexate	489	14.7	14.7
Methotrexate Sodium	533	14.2	14.2
Cladribine	13	13.5	13.5
Valacyclovir	55	13.4	13.4
Hydroxyurea	28	13.3	13.3
Imatinib	23	13.1	13.1
Piperacillin Sodium,Tazobactam Sodium	34	12.9	12.9
Everolimus Tablets	21	12.5	12.5
Prednisolone	196	11.8	11.8
Prednisolone Oral	196	11.8	11.8
Prednisolone Oral Solution	196	11.8	11.8
Indomethacin	14	10.5	10.5
Methylprednisolone Sodium Succinate	48	10.5	10.5
Filgrastim	39	10.4	10.5
Acyclovir	114	10.4	10.4
Vancomycin	58	10.2	10.2
Magnesium Sulfate In Water For	13	10.1	10.2
Piperacillin And Tazobactam	13	10.1	10.1
Rituximab	195	10.0	10.0
Magnesium Sulfate Heptahydrate	13	9.9	9.9
Methylprednisolone Acetate	8	9.9	9.9
Magnesium Sulfate	13	9.9	9.9
Vancomycin Hydrochloride	63	9.7	9.7
Human Immunoglobulin G	20	9.7	9.7
Valacyclovir Hydrochloride	64	9.2	9.3
Obinutuzumab	15	9.1	9.1
Dasatinib	32	8.6	8.7
Adalimumab-Fkjp	38	8.3	8.3
Daspone	8	8.2	8.2
Dapsone Gel, 5%	8	8.2	8.2
Adalimumab-Aaty	38	8.1	8.1
Thalidomide	29	7.9	7.9
Piperacillin Sodium And Tazobactam Sodium	15	7.6	7.6
Dapsone	8	7.4	7.5
Norepinephrine	8	7.4	7.4
Cefepime Hydrochloride	12	7.4	7.4
Adalimumab-Adaz	38	7.2	7.3
Norepinephrine Bitartrate	10	6.9	6.9
Levofloxacin	40	6.7	6.7
Levofloxacin In 5% Dextrose	40	6.7	6.7
Cefepime	9	6.2	6.2
Oseltamivir	5	6.2	6.2
Eltrombopag Olamine	14	6.0	6.1
Ifosfamide	13	6.0	6.0
Mesna Injection	5	6.0	6.0
Mesna	5	5.9	5.9
Granisetron Hydrochloride	6	5.7	5.7
Sofosbuvir	11	5.5	5.5
Daptomycin	5	5.4	5.4
Alteplase	8	5.3	5.3
Venetoclax	32	5.2	5.2
Doxorubicin	46	5.2	5.2
Entecavir	6	5.1	5.1
Romiplostim	7	4.6	4.6
Nilotinib	13	4.4	4.4
Bortezomib	37	4.2	4.2
Vedolizumab	34	4.0	4.0
Eculizumab	21	3.9	3.9
Carfilzomib	8	2.8	2.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.